Advanced progress in the genetic modification of the oncolytic HSV-1 virus
The use of replication-competent viruses for selective tumor oncolysis while sparing normal cells marks a significant advancement in cancer treatment. HSV-1 presents several advantages that position it as a leading candidate for oncolytic virotherapies. Its large genome can accommodate insertions ov...
Saved in:
Main Authors: | Mi Zhou, Zhenyu Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1525940/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving systemic delivery of oncolytic virus by cellular carriers
by: Ziyi Peng, et al.
Published: (2024-12-01) -
Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis
by: Joseph Malinzi, et al.
Published: (2018-11-01) -
A comparative study of replicative properties of antitumor recombinant vaccinia viruses on human glioblastoma cell culture U87 and monkey kidney cell culture CV-1
by: R. A. Maksyutov, et al.
Published: (2017-02-01) -
Genetic advancements in breast cancer treatment: a review
by: Marzieh Shokoohi, et al.
Published: (2025-02-01) -
Advances in preclinical and clinical studies of oncolytic virus combination therapy
by: Wenlong Du, et al.
Published: (2025-02-01)